SINGLETON J MATTHEW

Director J. Matthew Singleton sells 16,000 VKTX shares at $79.50 (-62.7% of holdings); stock -17.4% from $94.50 high despite +23.6% in 30 days.

Director J. Matthew Singleton sold 16,000 shares at $79.50 on 2024-10-25, reducing his holdings from 25,500 to 9,500 shares—a substantial -62.7% reduction. The sale occurred while VKTX stock trades -17.4% from its 52-week high of $94.50, suggesting the insider chose to exit after the stock had already retreated from peak valuations. This follows two prior sales by Singleton at the same ticker on 2024-08-14; his cross-ticker track record shows 2 prior sells averaging 30-day returns of +15.2%, indicating those earlier exits generally preceded further price appreciation. The company remains unprofitable with net income of $-24,940,000 and $0.00 revenue in the latest quarter, underlining the speculative nature of the investment. The timing of this large position reduction warrants attention given the company's financial position and the stock's recent retreat from its peak.

Director J Matthew Singleton sold 20,786 shares of VKTX (68.6% of holdings) for $1,195,736.22 at $57.53 blended average

Director J Matthew Singleton executed 2 separate sales totaling 20,786 shares for $1,195,736.22, reducing his holdings by 68.6% from 30,286 to 9,500 shares. This represents a material reduction in insider ownership at a company trading near its 52-week lows (current price $58.20 is 38.4% below the $94.50 52-week high). The sale occurs in the context of a therapeutics company reporting zero revenue in the latest quarter and cumulative losses of $22,250,000, with no path to profitability disclosed in recent fundamentals. The magnitude of the stake reduction — nearly 69% of the director's position — following sustained price weakness (90-day decline of 15.7%) warrants investor scrutiny regarding management's confidence in the company's near-term trajectory or capital allocation strategy.